BioNTech SE - American Depositary Shares (BNTX)
111.48
+0.00 (0.00%)
NASDAQ · Last Trade: Jul 30th, 5:36 AM EDT
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is pledging a major overhaul of the National Vaccine Injury Compensation Program (VICP), describing the system as fundamentally broken and failing its intended purpose.
Via Benzinga · July 28, 2025
AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data.
Via Benzinga · July 10, 2025
Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 vaccine patent dispute.
Via Benzinga · July 10, 2025
Via Benzinga · July 3, 2025
The committee cited remarks allegedly made by Philip Dormitzer at GSK, claiming that Pfizer’s top R&D leaders delayed clinical trial progress to avoid releasing results before the 2020 election.
Via Stocktwits · June 30, 2025
Via Benzinga · June 16, 2025
U.S. stocks edge higher as inflation cools, Oracle soars on AI growth, and markets brace for Israel-Iran conflict escalation.
Via Chartmill · June 13, 2025
BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline.
Via Benzinga · June 12, 2025
Under the terms of the deal, each CureVac share will be exchanged for approximately $5.46 in BioNTech American depositary shares.
Via Stocktwits · June 12, 2025
A sweeping overhaul of the CDC's top vaccine advisory panel is ripping through the medical world, while rattling pharma and biotech stocks.
Via Benzinga · June 10, 2025
Kennedy said the Department of Health and Human Services would retire all 17 current members of the ACIP, citing what he called a "crisis of public trust."
Via Stocktwits · June 10, 2025
A CDC committee in charge of making vaccine recommendations was gutted Monday to make way for a new coalition.
Via Investor's Business Daily · June 9, 2025

Via Benzinga · June 5, 2025

Via Benzinga · June 3, 2025

Wall Street Climbs Despite Trade Tensions: Steel Stocks Shine, Apple Impresses
Via Chartmill · June 3, 2025

Bristol Myers Squibb just agreed to shower BioNTech with cash.
Via The Motley Fool · June 2, 2025

BioNTech and Bristol Myers Squibb will co-develop BNT327 for solid tumors in a $1.5 billion deal with potential milestones totaling up to $7.6 billion.
Via Benzinga · June 2, 2025

BMS will pay BioNTech $1.5 billion in an upfront payment in the second quarter and $2 billion in non-contingent anniversary payments through 2028.
Via Stocktwits · June 2, 2025

Via Benzinga · June 2, 2025
RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed.
Via Benzinga · May 27, 2025
The U.S. Food and Drug Administration has announced significant changes to COVID-19 vaccine requirements, limiting annual booster approvals to older and high-risk Americans while implementing stricter clinical trial requirements for healthy adults.
Via Benzinga · May 21, 2025